Loading stock data…
Progyny, Inc. (PGNY)
$27.15+1.21 (+4.66%)
Market ClosedLast close Sep 8
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Progyny, Inc. in the Healthcare sector is trading at $27.15 with a market capitalization of $2.1B. Wall Street consensus targets $34.42 (12 analysts), implying a +26.8% move over the next 12 months. The stock is currently 18% below its 52-week high of $33.06, remaining 12.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +26.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $350.51M↑ | $328.50M↑ | $318.40M↑ | $313.35M↓ | $332.87M |
| Gross Profit | $89.30M↑ | $83.07M↑ | $76.88M↑ | $72.83M↓ | $78.97M |
| Operating Income | $40.00M↑ | $35.38M↑ | $15.22M↓ | $21.53M↓ | $24.36M |
| Net Income | $28.05M↑ | $24.23M↑ | $12.48M↓ | $13.86M↓ | $17.11M |
Peer Comparison
JNJUNHPFE
Fundamentals
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cyc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.08B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.51
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.35%
Volume
Today's trading volume
1.85M
Recent News
1 Russell 2000 Stock to Consider Right Now and 2 That Underwhelm
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
3 Healthcare Stocks We Steer Clear Of
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 24.9% over the past six months, topping the S&P 500 by 13.3 percentage points.
3 of Wall Street’s Favorite Stocks We Keep Off Our Radar
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns
MNDY, MTCH, PGNY and WK make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.
Wells Fargo Conceives a High Rating for the Fertility-Benefits Biz
What employees really want are fertility benefits, and there’s a market for providing them that’s underserved. Progyny provides family-focused services to about 7 million patients at more than 600 companies, but Wells Fargo sees a potential market of 156 million. The decade-old company made nearly $1.3 billion in revenue in the past fiscal year, up 10%, as it continued expanding beyond basic fertility services. Sign up for The Daily Upside at no cost for premium analysis on all your favorite stocks.